CRUSADE Bleeding Risk Score for ACS Patients
The CRUSADE bleeding risk score quantifies in-hospital major bleeding risk in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) using eight clinical variables.
About
The CRUSADE bleeding risk score was developed from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) registry. It quantifies in-hospital major bleeding risk in NSTE-ACS patients and uses eight variables: heart rate ≥70 bpm (2 pts), systolic BP <100 mmHg (3 pts), hematocrit <36% women / <40% men (9 pts), CrCl <30 (14 pts) or 30-60 mL/min (7 pts), diabetes (5 pts), vascular disease (3 pts), CHF (7 pts), and female sex (6 pts). Total score ranges from 0 to >50 with five risk categories.
Formula
HR ≥70 (2) + SBP <100 (3) + Low Hct (9) + Low CrCl (7-14) + Diabetes (5) + Vascular Disease (3) + CHF (7) + Female (6)
The CRUSADE score assigns weighted points based on eight clinical variables: heart rate ≥70 bpm (2 points), systolic BP <100 mmHg (3 points), low hematocrit (<36% in women, <40% in men; 9 points), creatinine clearance <30 mL/min (14 points) or 30-60 mL/min (7 points), diabetes mellitus (5 points), peripheral vascular disease (3 points), congestive heart failure (7 points), and female sex (6 points). The total score predicts in-hospital major bleeding risk. Categories: ≤20 very low (2.8% risk), 21-30 low (3.6%), 31-40 moderate (5.9%), 41-50 high (9.3%), >50 very high (13.4%).
Score Interpretation
The CRUSADE score is the most widely validated bleeding risk assessment tool for ACS patients undergoing invasive management. It was developed from over 71,000 patients in the CRUSADE registry and validated in multiple cohorts. The score helps guide antithrombotic choice, access site selection, and strategies to minimize bleeding complications.
Very Low Bleeding Risk — 0–20
In-hospital major bleeding risk 2.8%.
Management: Standard ACS management with low bleeding concern.
Low Bleeding Risk — 21–30
In-hospital major bleeding risk 3.6%.
Management: Standard management, routine monitoring.
Moderate Bleeding Risk — 31–40
In-hospital major bleeding risk 5.9%. Consider bleeding avoidance strategies.
Management: Consider radial access and bleeding avoidance strategies.
High Bleeding Risk — 41–50
In-hospital major bleeding risk 9.3%. Bleeding avoidance strategies recommended.
Management: Use bivalirudin or radial access. Consider shorter DAPT duration.
Very High Bleeding Risk — 51–999
In-hospital major bleeding risk 13.4%. Strongly consider bleeding avoidance.
Management: Strongly prefer radial access. Use bivalirudin monotherapy. Reduce antithrombotic intensity.
Reference Ranges
| Population | Normal Range | Notes |
|---|---|---|
| NSTE-ACS patients undergoing invasive management | 0 - 50+ points | Higher scores indicate higher in-hospital major bleeding risk |
Dr. Khaled Hassan
Dr. Khaled is a cardiology consultant with experience in acute cardiac care.
View medical review board & editorial policy →Example Calculation
A 72-year-old woman with NSTEMI, HR 95 bpm, SBP 130 mmHg, Hct 32%, CrCl 35 mL/min, diabetes, no vascular disease, no CHF. CRUSADE: HR 95 (2pts) + SBP 130 (0) + Hct 32%<36% (9) + CrCl 35 (7) + diabetes (5) + female (6) = 29 points — low bleeding risk. Standard management appropriate.
Related Conditions
Related Medications
Common Mistakes
Using CRUSADE for STEMI patients
CRUSADE was derived and validated in NSTE-ACS patients. For STEMI, consider other scores like ACTION or GRACE.
Using incorrect hematocrit threshold by sex
Women score 9 points if Hct <36%. Men score 9 points if Hct <40%. Ensure correct sex-specific threshold.
Frequently Asked Questions
How is CRUSADE different from HAS-BLED?
What is the maximum CRUSADE score?
References
- Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE bleeding score. Circulation. 2009;119(14):1873-1882. PubMed
- Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm. Circ Cardiovasc Interv. 2009;2(3):175-182. PubMed